Improving Islet Transplantation Outcomes With Gastrin

• ClinicalTrials.gov Identifier: NCT03746769
• Recruitment Status: Recruiting
• First Posted: November 20, 2018
• Last Update Posted: March 3, 2022
• Sponsor: City of Hope Medical Center
• Collaborator: University of California, Los Angeles
• Information provided by (Responsible Party): City of Hope Medical Center

Study Description

Brief Summary:

This clinical study will evaluate the safety and effectiveness of Gastrin treatment with islet transplantation to help patients with difficult to control type 1 diabetes make insulin again and improve blood sugar control.

This study involves two investigational (experimental) products not yet approved by the U.S. Food and Drug Administration (FDA) as a treatment for any disease:

1. Human allogenic islet cells (islet cells from a deceased, unrelated human donor)
2. Gastrin-17 (Gastrin) - a hormone secreted by the gut

Condition or disease	Intervention/treatment	Phase
Diabetes Mellitus, Type 1	Biological: Allogenic Human Islet Cells; Drug: Gastrin 17	Phase 1; Phase 2

Detailed Description:

Islet cell transplantation involves transplanting the cells that make insulin from a pancreas of deceased organ donor to a patient with diabetes. Because there is a limited supply of donor islet cells available, this study is testing whether Gastrin injections can help make a fewer number of transplanted islets work better.

Gastrin is a natural gut hormone that is present in the pancreas during its development in the embryo but not after birth, and is believed to participate in the formation of the normal pancreas. Several studies have tried to use gastrin to help grow insulin making islet cells in laboratory experiments or after transplanting islets in laboratory animals. In early clinical trials, diabetic patients treated with gastrin and other growth factors required less insulin after 4 weeks of gastrin treatment and the effect lasted more than 12 weeks after stopping treatment, suggesting that gastrin may have increased the number of cells that make insulin.

This study will evaluate whether taking Gastrin injections following a single islet transplantation is safe, improves how well the islet transplant works and/or helps increase the number of insulin-making cells in the islets.

Qualified participants will receive treatment with a single islet transplant, followed by two rounds of gastrin treatment (twice daily injections for 30 days) just after transplant and again 6 months later. Study participants will also take anti-rejection medications (to prevent the body from rejecting the islet cells) and other medications to guard against infection and support their health and/or the health of the transplanted islets. Participants will need to return to City of Hope in Duarte, CA for frequent follow-up visits for one year after transplant.

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 20 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: Improving Islet Transplantation Outcomes With Gastrin
• Actual Study Start Date: July 7, 2019
• Estimated Primary Completion Date: February 1, 2026
• Estimated Study Completion Date: February 1, 2026

Arms and Interventions

Arm

Intervention/treatment

Experimental: Single Arm Study

Biological: Allogenic Human Islet Cells; islet cells transplanted into the portal vein in the liver; Drug: Gastrin 17; Gastrin-17 (or GAST-17) - a gut hormone injected under the skin twice daily for 30 days soon after islet transplant and again 6 months later. Also, anti-rejection medications (to prevent the body from rejecting the islet cells) and other medications to guard against infection and support participant health and/or the health of the transplanted islets.

Outcome Measures

Primary Outcome Measures :

1. Proportion of subjects who are insulin independent, free from severe hypoglycemia and have HbA1c less than or equal to 6.5% ("complete response") [ Time Frame: 1 year post transplant (6 months after second course of Gastrin) ]

Secondary Outcome Measures :

1. Proportion of subjects who are free of severe hypoglycemic episodes (SHE) and have a HbA1c less than or equal to 7.0% ("partial response"). [ Time Frame: At Month 1, Month 2.5, and Month 6 post start of each Gastrin course ]

Other Outcome Measures:

1. Reduction/elimination of hypoglycemia [ Time Frame: At Month 1, Month 2.5, and Month 6 post start of each Gastrin course ]
2. Reduction in daily insulin use [ Time Frame: At Month 1, Month 2.5, and Month 6 post start of each Gastrin course ]
3. Reduction of daily insulin use per 100,000 IEQ transplanted [ Time Frame: At Month 1, Month 2.5, and Month 6 post start of each Gastrin course ]
4. C-peptide/insulin secretion response to glucose/arginine stimulation and other metabolic studies. [ Time Frame: At Month 1, Month 2.5, and Month 6 post start of each Gastrin course ]
5. Incidence of treatment-related adverse events [ Time Frame: At Month 1, Month 2.5, and Month 6 post start of each Gastrin course ]
6. Incidence of a change in immunosuppression drug regimen [ Time Frame: At Month 1, Month 2.5, and Month 6 post start of each Gastrin course ]
7. The incidence of immune sensitization defined by presence of anti-HLA antibodies absent prior to transplant [ Time Frame: At Month 1, Month 2.5, and Month 6 post start of each Gastrin course ]
8. Incidence of discontinuation of immunosuppression [ Time Frame: At Month 1, Month 2.5, and Month 6 post start of each Gastrin course ]
9. Incidence of change or early discontinuation of Gastrin treatment [ Time Frame: At Month 1, Month 2.5, and Month 6 post start of each Gastrin course ]
10. Incidence of change or early discontinuation of sitagliptin/esomeprazole supportive therapy [ Time Frame: At Month 1, Month 2.5, and Month 6 post start of each Gastrin course ]
11. Improvement in glucose time in range during continuous glucose monitoring [ Time Frame: At Month 1, Month 2.5, and Month 6 post start of each Gastrin course ]
12. Improvement in Personal Glycemic State (PGS) score calculated from continuous glucose monitoring [ Time Frame: At Month 1, Month 2.5, and Month 6 post start of each Gastrin course ]

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 68 Years (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

1. Age 18-68 years
2. Type 1 diabetes mellitus (documented with fasting C-peptide level of </= 0.2 ng/ml before and </= 0.3 ng/ml after IV administration of 1 mg of glucagon) for at least 5 years.

3. Unstable blood glucose characterized by:

   Frequent hypoglycemia (blood glucose less than or equal to 54 mg/dl more than once per week)

   -and/or- Hypoglycemia unawareness (Clarke score of 4 or more).

   -and/or- One or more severe hypoglycemic episodes in 12 months preceding enrollment

   -and/or- Erratic blood glucose levels that interfere with daily activities

   -and/or- One or more hospital visits for diabetic ketoacidosis in the 12 months preceding enrollment

4. Ability and willingness to comply with post-transplant regimen, including immunosuppression, use of reliable contraception, frequent clinic visits, testing and maintaining detailed logs of blood glucose levels, insulin doses and medications, and completing detailed follow-up studies.
5. Ability to give informed consent.

Exclusion Criteria:

1. BMI > 33
2. Insulin requirements > 1.0 units/kg/day
3. Significant kidney disease (estimated GFR from serum creatinine measurement <65 ml/min, random spot urine microalbumin to creatinine ratio >300mg albumin/g creatinine)
4. Significant hepatobiliary disease, including elevation of liver enzymes > twice the upper limit of normal for each of ALT and AST (any elevation of these enzymes will be determined), bilirubin not within normal limits, albumin < 3.5 g/dl, liver masses, portal vein thrombosis, evidence of portal hypertension, or significant, untreated gallbladder disease (i.e. gallstones)
5. Significant cardiovascular disease, including non-correctable coronary artery disease with ejection fraction < 50% and/or recent myocardial infarction (within last 12 months); or extensive peripheral vascular disease not correctable by surgery,
6. Evidence of active proliferative retinopathy
7. Hypertension( >/= 140/90) despite appropriate treatment
8. Hyperlipidemia (total cholesterol > 260 mg/dl, LDL > 160 mg/dl, and/or triglycerides > 300 mg/dl) despite appropriate treatment
9. Anemia (Hgb < 11 g/dl) or other hematologic disorders that require medical attention
10. WBC <3,000/ul
11. Increased risk of bleeding (platelet count < 120,000 cells/ul; INR > 1.5), other chronic hemostasis disorders, or treatment with chronic anticoagulant therapy (i.e. heparin or warfarin)
12. Recent unresolved acute infection (except for mild skin infection or nail fungal infection), or chronic infection, including tuberculosis, HIV, HBV, HCV, CMV or syphilis (RPR)
13. EBV IgG negative
14. Any history of malignancy, except completely resected squamous or basal cell skin cancer or in situ cancer of the cervix
15. Evidence of active peptic ulcer disease
16. History of gastric bypass
17. Recent history of non-adherence to recommended medical therapy
18. Psychiatric illness that is untreated, or likely to interfere significantly with study compliance despite treatment
19. Previous organ/tissue transplant
20. Administration of live attenuated vaccines within 60 days of enrollment.
21. Presence of a chronic disease that must be chronically treated with contraindicated medications
22. Use of investigational agents within four weeks of enrollment
23. Active alcohol or substance abuse, including cigarette smoking (must be abstinent for > 3 months)
24. Pregnant women, women intending future pregnancy, women of reproductive potential who are unable or unwilling to follow effective contraceptive measures (i.e., tubal ligation, two barrier methods, abstinence) for the duration of study treatment and for as long as they are on immunosuppressive medication, and women presently breastfeeding.
25. Individuals without health insurance covering the cost of immunosuppression and clinical and laboratory follow-up after completion of the study
26. Any medical condition that in the opinion of the investigator will interfere with safe participation in the trial

Contacts and Locations

Contacts

Contact: Arthur Riggs Diabetes & Metabolism Research Institute at COH; 1-866-44-ISLET(1-866-444-7538); Islets@coh.org

Locations

United States, California

City of Hope Medical Center; Recruiting

Duarte, California, United States, 91010

Principal Investigator: Fouad Kandeel, MD, PhD

Sponsors and Collaborators

City of Hope Medical Center

University of California, Los Angeles

Investigators

• Principal Investigator: Fouad Kandeel, MD, PhD; City of Hope Medical Center

More Information

Additional Information:

City of Hope Islet Cell Transplantation Program 

• Responsible Party: City of Hope Medical Center
• ClinicalTrials.gov Identifier: NCT03746769
• Other Study ID Numbers: 18156
• First Posted: November 20, 2018
• Last Update Posted: March 3, 2022
• Last Verified: February 2022

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

Keywords provided by City of Hope Medical Center:

islet; islet cell; transplant; gastrin; hypoglycemia; labile diabetes

Additional relevant MeSH terms:

Diabetes Mellitus, Type 1; Diabetes Mellitus; Glucose Metabolism Disorders; Metabolic Diseases; Endocrine System Diseases; Autoimmune Diseases; Immune System Diseases; Gastrins; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Physiological Effects of Drugs